§01 — Pharmaco-epigenomics
Everyone's getting sequenced. Almost no one gets an answer.
Whole-genome sequencing is everywhere — and mostly inert. The actionable layer isn't the sequence you inherited; it's the methylome: the regulatory state your cells are in right now. MethylGKB reads it from a single whole-blood methylation array and turns it into pharmacogenomic insight — what will work, what won't, what's toxic.
§02 — The white space
There is no PharmGKB for methylation. We're building it.
Drug-response knowledge splits into two worlds that rarely touch — germline variant guidelines and cancer cell-line screens — and neither curates methylation. The one portal that integrates it isn't a knowledge base. That empty quadrant is the product.
§03 — Why sequence isn't enough
The genome says who you are. The methylome says what to do about it.
What WGS gives you
A fixed inheritance. Powerful for rare-disease and a handful of germline pharmacogenes — but for most patients it returns variants of uncertain significance and little a clinician can act on today. It can't see regulatory state, environment, or how a cell is actually behaving.
What the methylome gives you
A live regulatory readout from whole blood. Methylation already carries the canonical, clinically deployed drug biomarker (MGMT → temozolomide), predicts cytotoxic response on its own, and changes with disease and exposure. It's the layer where the actionable signal lives — and it's cheap to read.
§04 — What MethylGKB is
A curated knowledge base of methylation → drug-response associations.
Every association is a structured, evidence-graded claim: a methylation locus that predicts response to a drug, with its grade, provenance, and the contradictions it lives among — retained, not smoothed over.
The claims
Locus → predicts-response-to → drug, each pre-graded (PharmGKB 1A–4 / CPIC A–D) and provenance-stamped. Browse, filter, cite.
Explore →The science
Why methylation predicts drug response, where it's proven, where it isn't, and the discordances that make this a frontier.
Read the wedge →The readout
One whole-blood methylome → an evidence-graded PGx report: favorable, caution, avoid — with the claim behind every call.
See a report →§05 — Where it goes
A knowledge base that grows itself.
MethylGKB sits on Polymer's formal-claims substrate. Contradictions — like FDA vs CPIC — aren't errors to resolve; they're the richest seed. An agent walks the base, finds tensions and gaps, proposes the conditioning variable that reconciles them, verifies each new claim against its own evidence, and integrates it. Knowledge accumulates instead of evaporating.